{"groups":[{"description":"Treatment phase (28 days/cycle x 6 cycles):\n\nLenalidomide: 10 mg/day orally on days 1-21, followed by 7 days of rest. Melphalan: 4 mg/m2 daily on days 1-4. Dexamethasone: 40 mg daily on days 1, 8, 15 and 22.\n\nMaintenance Phase (for subjects who achieve partial response or better at the end of the treatment phase):\n\nlenalidomide: 10 mg/day orally on days 1-21 followed by 7 days of rest (28 days/cycle) for a maximum of 24 cycles.","id":"FG000","title":"ReMeDex"}],"periods":[{"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"8"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"1"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"7"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}],"preAssignmentDetails":"Total 8 patients were enrolled. One patient withdrew before the treatment started.","recruitmentDetails":"Patients were enrolled from NYU medical center and its affiliated hospitals from Dec 2008 through Apr 2011."}